'6 Israeli start-ups will be floated on Nasdaq next year'

David Enzer, a managing director at Roth Capital Partners, believes in an Israeli revival on Wall Street, isn't concerned at competition from China.

By BATYA FELDMAN
October 27, 2010 23:10
3 minute read.
David Enzer

David Enzer Managing Partner at Roth Capital Partners. (photo credit: Courtesy)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

“Over the coming year, at least six Israeli venture-backed companies will hold successful IPOs on Nasdaq. Investors are showing interest in Israeli technology companies, and I believe there’s a big opportunity here,” said David Enzer, a managing director at US investment bank Roth Capital Partners, which specializes in banking services for small-cap companies.

Enzer will be in Israel at the end of the month, to participate in the Ernst & Young-Globes Journey Conference. In an exclusive interview with Globes, he said: “In the next year, there will be a revival of interest among US investors. We are seeing extraordinary Israeli companies, particularly in semiconductors, media and telecommunications.”

Be the first to know - Join our Facebook page.


Roth Capital, based on the West Coast, was founded in 1984. In the 1990s, it was an underwriter for IPOs by smallcap companies. With the changes that the public market underwent, it began to promote PIPE (private investment in public equity) financings. Given recent SEC rule changes allowing shelf offerings for small-cap companies, Roth is very active there.

Roth was also one of the first banks to offer services to small Chinese companies active in the United States and traded there. It is a full-service investment bank, active in fund raising, research coverage, trading, and mergers and acquisitions. To date, Roth has helped its customers raise $10.6 billion, and it has been involved in 150 mergers and acquisitions. Since 2003, Roth has completed more than 67 deals worth a total of $2.8b. in Chinese companies listed in the US.

The first deal in which Enzer was involved in Israel was the financing of ART Advanced Recognition Technologies in 1998. The company was sold to Nuance Communications in 2004. Roth Capital itself has been involved in various kinds of deals with 10 other Israeli technology companies, among them Nova Measuring Instruments Ltd., Lanoptic, EZchip Semiconductor Ltd., Pluristem Therapeutics Ltd. and Orckit Communications Ltd., and also in non-technology companies, such as G. Willi-Food Investments Ltd.

Given your optimistic outlook, do you understand why there are those ready to write off Israeli hi-tech and venture capital?

“I’m surprised to hear it. From here, it looks as though there are exciting companies in the Israeli market, and as though there will be no shortage of investment banks that will want to take them public.



“I hear that the atmosphere is sour, but we see in Israel opportunities and successful companies, chiefly in semiconductors and infrastructures. They have a fantastic business. Some of them are growing at rates in the hundreds of percentage points, don’t need money and look like they will become market leaders. I’m talking about companies like BroadLight, Siano and Provigent.”

According to Enzer, Roth’s advantage is its experience in providing services to small companies.

“We don’t work with companies that have valuations of billions of dollars,” he said. “Over the years, we have mostly led managed deals for small-cap companies that have market caps of $100 [million] to $500 million. We know the market very well, and we know the fund managers that care about small caps; there are a lot of them.”

The fear is that Chinese companies will take the place of the Israeli companies that used to reach Nasdaq in the past.

“If you look at the Chinese companies that have made successful IPOs, you’ll find that most of them are consumeror industrial-services companies, and not necessarily technology companies. They attract a certain kind of investor. Investors who seek technology companies look at companies in Silicon Valley and in Israel.”

Enzer does not sound concerned about the high threshold set by Nasdaq for companies that want to join. He believes “the market will now switch to growth,” adding that “there are many good, promising companies.”

Despite the lack of clarity in the capital markets, there is a list of 100 companies registered for IPOs, a third of them technology companies, he said, adding, “Companies with revenue of $40 [million] to $50 million are already on the runway.”

The feeling is that only profitable companies, with annual revenue in the hundreds of millions of dollars, are fit to make IPOs.

“There are several companies registered for flotation with revenue of $50 million, most of them growing impressively, and investors also want to see positive EBITDA.

But even companies close to profitability, that show future growth and will be profitable within three to four quarters, interest investors.”

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS